Proximagen proposes £30m IPO

Drug developer Proximagen, a spin out from King’s College, will join AIM at the end of the month with a £30 million starting price tag.

Founded by Professor Peter Jenner and focusing on neurodegenerative disease, the company plans to pull in up to £12 million from institutions to finance its drug development programmes in Parkinson’s and Alzheimer’s diseases.

AIM-quoted IP2IPO, the university technology IP counter fronted by chess expert David Norwood, holds a pre-placing 46.1 per cent.

KBC Peel Hunt will act as broker and adviser.

For further information visit:

Proximagen
IP2IPO

Leslie Copeland

Leslie was made Editor for Growth Company Investor magazine in 2000, then headed up the launch of Business XL magazine, and then became Editorial Director in 2007 for the online and print publication portfolio... More by Leslie Copeland

Proximagen proposes £30m IPO

Drug developer Proximagen, a spin out from King’s College, will join AIM at the end of the month with a £30 million starting price tag.

Leslie Copeland

Related Stories

General Election 2024 – what do scale-ups want to see?

ThinCats to back high-growth companies with £300m fund

Fastest-growing companies in the UK revealed

Litestream Ventures unveils plans for ‘click-to-invest’ TV series

Related Topics